RecruitingPhase 1Phase 2NCT05957367

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Sponsor

Deciphera Pharmaceuticals, LLC

Enrollment

94 participants

Start Date

Sep 28, 2023

Study Type

INTERVENTIONAL

Conditions

GIST

Summary

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Inlexisertib and a drug called Ripretinib for people with gist. The study is currently recruiting participants at 26 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInlexisertib

Oral Tablet Formulation

DRUGRipretinib

Oral Tablet Formulation

Locations(28)

University of Southern California - Norris Comprehensive Cancer Center

Los Angeles, California, United States

UCLA Department of Medicine-Hematology/Oncology

Los Angeles, California, United States

Sylvester Comprehensive Cancer Center

Miami, Florida, United States

University of Massachusetts Worcester

Worcester, Massachusetts, United States

START Midwest

Grand Rapids, Michigan, United States

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center - Main Campus

New York, New York, United States

Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Virginia Cancer Specialist, PC

Fairfax, Virginia, United States

Aarhus University Hospital

Aarhus, Denmark

Centre Oscar Lambret

Lille, France

Institut Curie, Service d'Oncologie Médicale

Paris, France

Hôpital Européen Georges Pompidou

Paris, France

Universitatsklinikum Franfurt

Frankfurt, Germany

Universitätsklinikum Eppendorf

Hamburg, Germany

AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial

Florence, Italy

IRCCS Azienda Ospedaliera Metropolitana

Genova, Italy

Istituto Europeo di Oncologia

Milan, Italy

Antonie Van Leeuwenhoek Hospital

Amsterdam, Netherlands

Radboudumc

Nijmegen, Netherlands

Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E.

Porto, Portugal

ICO Hospitalet

Barcelona, Spain

Hospital Universitario Ramón y Cajal

Madrid, Spain

Hospital Universitario Clinico San Carlos

Madrid, Spain

Hospital Universitario Virgen Del Rocio

Seville, Spain

Inselspital Universitätsklinikum Bern

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05957367

Related Trials

A Study of Olverembatinib in SDH-deficient GIST.

NCT066403611 location

LRG GIST Patient Registry

NCT076972481 location

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT0740663316 locations

Familial Investigations of Childhood Cancer Predisposition

NCT030502681 location

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations